German pharmaceutical company Merck KGaA (MRK.XE) said Tuesday it has appointed Stefan Oschmann as its new Chief Executive as of April 2016.
Mr. Oschmann will succeed Karl-Ludwig Kley, who has been CEO since April 2007 and is now retiring.
Born July 25, 1957 in Wuerzburg, Germany, Mr. Oschmann has served as member of the Merck executive board since 2011. He was initially in charge of its pharmaceutical business before being appointed deputy chairman of the executive board and deputy CEO at the start of 2015.
Before joining Merck, Mr. Oschmann worked at Merck & Co. of the U.S., which holds rights to the Merck designation but isn’t affiliated with the German Merck.
“We’re … happy to have found a successor in Stefan Oschmann early on, whose strategic foresight and strong leadership have turned Merck into a respected player in the pharma industry again,” said Johannes Baillou, chairman of the board of partners at E. Merck KG.
By Natascha Divac
Source: Wall Street Journal via MarketWatch
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.
